| Study | Reason for exclusion |
|---|---|
| Albani 2006 | Conversion to monotherapy design, monotherapy comparison not possible |
| Alsaadi 2002 | Conversion to monotherapy design, monotherapy comparison not possible |
| Alsaadi 2005 | Conversion to monotherapy design, monotherapy comparison not possible |
| Baxter 1998 | Participants randomised to LTG and physician's choice of CBZ or VPS. No fully randomised comparison between the drugs |
| Ben‐Menachem 2003 | Conversion to monotherapy design, monotherapy comparison not possible |
| Beydoun 1997 | Conversion to monotherapy design, monotherapy comparison not possible |
| Beydoun 1998 | Conversion to monotherapy design, monotherapy comparison not possible |
| Beydoun 2000 | Conversion to monotherapy design, monotherapy comparison not possible |
| Bittencourt 1993 | Conversion to monotherapy design, monotherapy comparison not possible |
| Canadian Group 1999 | Conversion to monotherapy design, monotherapy comparison not possible |
| Cereghino 1974 | Cross‐over design is not appropriate for measuring long‐term outcomes |
| Chung 2012 | Conversion to monotherapy design, monotherapy comparison not possible |
| DeToledo 2000 | Conversion to monotherapy design, monotherapy comparison not possible |
| EUCTR2004‐004053‐26‐SE | Trial terminated early, no results available |
| EUCTR2010‐018284‐42‐NL | Trial terminated early, no results available |
| Fakhoury 2004 | Conversion to monotherapy design, monotherapy comparison not possible |
| French 2012 | Conversion to monotherapy design, monotherapy comparison not possible |
| Gilliam 1998 | Conversion to monotherapy design, monotherapy comparison not possible |
| Gruber 1962 | Cross‐over design is not appropriate for measuring long‐term outcomes |
| Hakami 2012 | Conversion to monotherapy design, monotherapy comparison not possible |
| ISRCTN73223855 | Trial terminated early, no results available |
| Kaminow 2003 | Participants randomised to LTG and physician's choice of CBZ PHT or VPS. No fully randomised comparison between the drugs |
| Kerr 1999 | Conversion to monotherapy design, monotherapy comparison not possible |
| Kerr 2001 | Conversion to monotherapy design, monotherapy comparison not possible |
| Loiseau 1984 | Cross‐over design is not appropriate for measuring long‐term outcomes |
| Reinikainen 1984 | Conversion to monotherapy design, monotherapy comparison not possible |
| Reinikainen 1987 | Conversion to monotherapy design, monotherapy comparison not possible |
| Rosenow 2012 | Conversion to monotherapy design, monotherapy comparison not possible |
| Simonsen 1975a | Conversion to monotherapy design, monotherapy comparison not possible |
| Simonsen 1975b | Conversion to monotherapy design, monotherapy comparison not possible |
| Taragano 2003 | Included participants primarily had dementia, only a subset had epilepsy |
CBZ: carbamazepine; LTG: lamotrigine; PHT: phenytoin; VPS: sodium valproate